Career
Why work at PRECISIS?
Success Stories
Job Openings
Aktuell sind keine offenen Stellen ausgeschrieben.
Didn’t find the right role?
Send us your speculative application! Start your application process now.
Benefits
*These benefits vary by role and country and do not apply to all positions.
Application Process
Step 1
Step 2
Step 3
This is Us
FAQ: Frequently Asked Questions
News
-
Read more: FDA Greenlights Pivotal Study of PRECISIS’ Minimally Invasive Brain-Stimulation Therapy for Drug-Resistant Epilepsy

Heidelberg
Published:FDA Greenlights Pivotal Study of PRECISIS’ Minimally Invasive Brain-Stimulation Therapy for Drug-Resistant Epilepsy
PRECISIS, a German neurotechnology company developing minimally invasive brain-stimulation therapies, has received FDA authorization to begin a pivotal clinical trial of its EASEE® system for drug-resistant focal epilepsy – a step that moves the company closer to entering the U.S. market. The pivotal study, following the device’s Breakthrough Designation, will evaluate safety and efficacy in…
-
Read more: European Investment Bank Backs Precisis with €20M Loan to Advance Breakthrough Neurostimulation Therapy in UK, Europe and US Markets
Published:European Investment Bank Backs Precisis with €20M Loan to Advance Breakthrough Neurostimulation Therapy in UK, Europe and US Markets
Heidelberg/Berlin, July 24 2025. Precisis, a Heidelberg-based MedTech innovator developing personalized neurostimulation technology for neurological disorders, announced today the closing of a €20 million venture loan from the European Investment Bank (EIB). This funding complements the company’s recently started efforts to raise an additional €37 million in equity financing as part of its Series B…
Discover more from PRECISIS
PRECISIS GmbH, based in Heidelberg, develops bioelectronic therapies that target the very source of neurological diseases – the brain itself. Learn more about our technology, our team, and the vision behind EASEE® for epilepsy.
About PRECISIS
News
Product
Career































